RecruitingPhase 2NCT07049848
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
Studying OBSOLETE: Pleomorphic undifferentiated sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Ahsan S Farooqi, MD, PHDM.D. Anderson Cancer Center
- Intervention
- Atezolizumab(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07049848 on ClinicalTrials.govOther trials for OBSOLETE: Pleomorphic undifferentiated sarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1NCT05813327Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue SarcomaWashington University School of Medicine
- ACTIVE NOT RECRUITINGNANCT05776667Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue SarcomaMedical University of South Carolina
- RECRUITINGNANCT05944913Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After RadiotherapyCentre Leon Berard
- RECRUITINGPHASE3NCT05597917tTF-NGR Randomized Study - STSUniversität Münster
- RECRUITINGNANCT04946357Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With IonsUniversity Hospital Heidelberg
See all trials for OBSOLETE: Pleomorphic undifferentiated sarcoma →